Exclusive Summary

• Levofloxacin eye drops are widely included in the WHO Essential Medicines List and multiple guidelines, serving as a first-line/second-line treatment for bacterial eye infections.
• High global incidence of bacterial conjunctivitis and keratitis forms a multi-hundred-million-dollar market, with preservative-free formulations meeting specific patient needs.
• The original patent has expired for many years, making it a mature market where high-quality, low-cost generics are attractive to most countries.
• Chinese suppliers, with international certifications and extensive registration experience, can offer GMP-compliant and price-competitive products, facilitating market access.
• The preservative-free 0.4ml/1.952mg single-dose packaging reduces waste and improves compliance for children and sensitive patients, offering a differentiated competitive advantage.